Rare cancer presentation: young adult with abdominal pain and a pancreatic mass
A 19-year-old man presents with a 2-month history of vague abdominal pain, weight loss, and jaundice. Imaging reveals a 4-cm mass in the head of the pancreas with biliary obstruction. His CA 19-9 is normal. He has no family history of pancreatic cancer. Endoscopic ultrasound-guided fine-needle aspiration shows a poorly differentiated neoplasm with uncertain origin. Immunohistochemistry is pending. The patient is otherwise healthy and works as a mechanic. The differential includes pancreatic adenocarcinoma, solid pseudopapillary neoplasm, neuroendocrine tumor, and lymphoma.
1. What is the differential diagnosis and what additional studies are needed to establish the diagnosis?
Read the worked answer
The differential includes pancreatic adenocarcinoma (rare in this age group but possible), solid pseudopapillary neoplasm (more common in young women but can occur in men), pancreatic neuroendocrine tumor, acinar cell carcinoma, lymphoma, and metastases. Additional studies: immunohistochemistry on the FNA cell block for markers such as cytokeratin, synaptophysin, chromogranin, CD56, beta-catenin, and lymphoid markers. Molecular testing for gene fusions (e.g., NRG1, ALK) may be considered if adenocarcinoma is suspected. If the diagnosis remains unclear, a core needle biopsy or surgical resection may be needed. Serum tumor markers (AFP, beta-hCG, LDH) to rule out germ cell tumor. Given the patient's age, genetic testing for hereditary cancer syndromes (e.g., BRCA, PALB2, Lynch syndrome) should be considered if adenocarcinoma is confirmed.
2. How would you approach the multidisciplinary management once the diagnosis is confirmed as a rare pancreatic tumor?
Read the worked answer
Management depends on the specific diagnosis. For solid pseudopapillary neoplasm, surgical resection is curative in most cases. For neuroendocrine tumors, treatment may include surgery, somatostatin analogs, or targeted therapy. For pancreatic adenocarcinoma, neoadjuvant chemotherapy followed by resection if borderline resectable, or palliative chemotherapy if unresectable. Given the patient's young age and good performance status, aggressive treatment with curative intent should be considered. A multidisciplinary tumor board should review the pathology and imaging. Fertility preservation should be discussed before starting chemotherapy. Genetic counseling and testing are important because of the young age and potential hereditary syndrome. Psychosocial support for the patient and family is essential.